Cancellation & Reissue Share Options

RUA Life Sciences PLC

10 December 2025

 

10 December 2025

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Cancellation & Reissue Share Options, PDMR Notice

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces that it has today cancelled, for nil consideration, certain options previously granted on 19 June 2024.

An administrative oversight following grant resulted in such options failing to be registered for EMI.  The board have therefore agreed to rectify this through the cancellation and re-grant, to put the employees in no worse position than they would have been.

An equivalent number of new options have therefore been granted over ordinary shares of 5 pence each in the Company ("Options") under the Enterprise Management Incentive (EMI) share option scheme.  The number, exercise price and the vesting terms and conditions of the new Options are the same as the options cancelled.

A total of 2,900,000 EMI Options have been granted, allocated as follows:

Name	Options cancelled (19 June 2024 Grant)	Options Granted (re-Grant)	Plan	Exercise price
William Brown	1,400,000	1,400,000	EMI	11 pence
Lachlan Smith	1,200,000	1,200,000	EMI	11 pence
Other employees	300,000	300,000	EMI	11 pence

Vesting and exercise

·      Options vest on 19 June 2027 (three years after original grant) and are exercisable up to the plan long-stop (10 years from original grant).

·      In the event of an offer to acquire the whole company prior to the plan long-stop date, vesting may accelerate in accordance with plan rules.

·      If a return of capital is proposed at an amount per share that is greater than the exercise price per share of these options, they will vest immediately prior to such return of capital to allow option holders to participate.

Following the cancelation and issuance of these share options, the Company had and will continue to have 5,625,603 shares under option being 9 % of the issued share capital of the Company.

For further information contact:

RUA Life Sciences Bill Brown, Chairman Lachlan Smith, CFO	Tel: [phone] Tel: [phone]
Cavendish Capital Markets Limited                               (Nominated Adviser and Broker) Giles Balleny/Isaac Hooper (Corporate Finance) Harriet Ward (Broking) Nigel Birks (Healthcare Specialist Sales) Michael Johnson (Sales)	Tel: [phone]

1		Details of the person discharging managerial responsibilities / person closely associated
a)	Name			1.     William Brown 2.     Lachlan Smith
2		Reason for the notification
a)	Position/status			1.     Chief Executive Officer 2.     Chief Financial Officer
b)	Initial notification /Amendment			Initial Notification
3		Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name			Rua Life Sciences Plc
b)	LEI			213800BMVB22PVOJ9Z28
4		Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument			Options over Ordinary Shares of £0.05 each
	Identification code			ISIN: GB0033360586
b)	Nature of the transaction			Grant and cancellation of options
c)	Price(s) and volume(s)
					Price(s)	Volume(s)
				1.	£0.11 (Grant)	1,400,000
					£0.11 (Cancellation)	1,400,000
				2.	£0.11 (Grant)	1,200,000
					£0.11 (Cancellation)	1,200,000
d)	Aggregated information
	- Aggregated volume			N/A
	- Price			N/A
e)	Date of the transaction			10 December 2025
f)	Place of the transaction			Outside a trading venue

 

END